Echinacoside promotes bone regeneration by increasing OPG/RANKL ratio in MC3T3-E1 cells

被引:128
作者
Li, Fei [1 ]
Yang, Yanan [2 ]
Zhu, Panpan [1 ]
Chen, Weina [1 ]
Qi, Dongli [1 ]
Shi, Xiupu [1 ]
Zhang, Chunfeng [1 ]
Yang, Zhonglin [1 ]
Li, Ping [1 ]
机构
[1] China Pharmaceut Univ, State Key Lab Nat Prod & Funct, Nanjing 210009, Jiangsu, Peoples R China
[2] Shanghai 1 Biochem & Pharmaceut Co Ltd, Inst Mat Med, Shanghai 200240, Peoples R China
关键词
MC3T3-E1; cell; OPG/RANKL; Osteoporosis; Bone regeneration; Echinacoside; RECEPTOR ACTIVATOR; DIFFERENTIATION; OSTEOPROTEGERIN; EXPRESSION; DENSITY;
D O I
10.1016/j.fitote.2012.08.008
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
Echinacoside (ECH), isolated from Cistanche tubulosa (Schrenk) R. Wight stems, was subjected to in vitro experiments to investigate its bioactivities on proliferation, differentiation and mineralization of the osteoblastic cell line MC3T3-E1. MTT assay, the alkaline phosphatase (ALP) activity and calcium deposition were determined, and the secretion of collagen I (COL I), osteocalcin (OCN), osteoprotegerin (OPG) and receptor activator of nuclear factor-kappa B ligand (RANKL) were also assayed by enzyme-linked immunosorbent assay (ELISA). The results showed that ECH caused a significant increase in cell proliferation. ALP activity, COL I contents, OCN levels and an enhancement of mineralization in osteoblasts at the concentration range from 0.01 to 10 nmol.L-1 (p<0.05), suggesting that ECH has a stimulatory effect on osteoblastic bone formation or has potential activity against osteoporosis. In addition, the ratio of OPG/RANKL also could be enhanced by ECH. These findings provide the potent evidence that ECH can promote bone regeneration in cultured osteoblastic MC3T3-E1 cells, which might be done by elevating the OPG/RANKL ratio, and potential evidence for echinacoside to be a promising drug or a lead compound in the development of disease-modifying drug to prevent osteoporosis. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:1443 / 1450
页数:8
相关论文
共 23 条
[1]
ARE MG-63 AND HOS TE85 HUMAN OSTEOSARCOMA CELL-LINES REPRESENTATIVE MODELS OF THE OSTEOBLASTIC PHENOTYPE [J].
CLOVER, J ;
GOWEN, M .
BONE, 1994, 15 (06) :585-591
[2]
Hormone replacement therapy: current controversies [J].
Davison, S ;
Davis, SR .
CLINICAL ENDOCRINOLOGY, 2003, 58 (03) :249-261
[3]
Rhusonoside A, a New Megastigmane Glycosoide from Rhus sylvestris, Increases the Function of Osteoblastic MC3T3-E1 Cells [J].
Ding, Yan ;
Nguyen, Huu Tung ;
Choi, Eun Mi ;
Bae, KiHwan ;
Kim, Young Ho .
PLANTA MEDICA, 2009, 75 (02) :158-162
[4]
The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases [J].
Hofbauer, LC ;
Heufelder, AE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (07) :2355-2363
[5]
EFFECTS OF BORDETELLA-BRONCHISEPTICA DERMONECROTIC TOXIN ON THE STRUCTURE AND FUNCTION OF OSTEOBLASTIC CLONE MC3T3-E1 CELLS [J].
HORIGUCHI, Y ;
NAKAI, T ;
KUME, K .
INFECTION AND IMMUNITY, 1991, 59 (03) :1112-1116
[6]
Antiosteoporotic activity of phenolic compounds from Curculigo orchioides [J].
Jiao, Lei ;
Cao, Da-Peng ;
Qin, Lu-Ping ;
Han, Ting ;
Zhang, Qiao-Yan ;
Zhu, Zheng ;
Yan, Fei .
PHYTOMEDICINE, 2009, 16 (09) :874-881
[7]
KOBAYASHI H, 1987, CHEM PHARM BULL, V35, P3309
[8]
Kodama HA, 1981, JPN J ORAL BIOL, V23, P891
[9]
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength [J].
Kostenuik, PJ .
CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (06) :618-625
[10]
Comparison of neoeriocitrin and naringin on proliferation and osteogenic differentiation in MC3T3-E1 [J].
Li, Lina ;
Zeng, Zhen ;
Cai, Guoping .
PHYTOMEDICINE, 2011, 18 (11) :985-989